Regeneron Pharmaceuticals Inc. reported data from a late-stage clinical trial suggest that its antibody cocktail therapy for covid-19 significantly reduces virus levels and the need for more medical attention.
(What is Trump’s experimental cocktail against covid-19?).
The results offer another encouraging sign in the race to find treatments for the deadly virus.
Out-of-hospital patients who received the therapy were 57% less likely to need medical care later, while 2.8% of the antibody recipients and 6.5% of the placebo recipients saw a worker health care within 29 days.
(Regeneron treatment against covid-19 shows positive results).
The New York-based company Tarrytown has shared the results with US regulators, who is currently evaluating the antibody cocktail for emergency use authorization in high-risk patients with mild to moderate COVID-19.
President Donald Trump was given Regeneron therapy earlier this month after he tested positive for the coronavirus.
Actions Regeneron rose 3.1% in after-hours trading in New York on Wednesday.
(Regeneron treatment would be against the coronavirus in six months).
Until closing, The stock was up 51% this year, driven largely by hopes that antibody therapy will soon offer doctors a powerful treatment option for the virus.
Because the therapy has had similar benefit in high and low doses, Regeneron is considering a change in the dose he uses in other ongoing outpatient studies.
A change to a lower dose could help extend the limited supply of the drug available.
The treatment appeared to be the most powerful for those most at risk, including older patients and those with other medical conditions, such as obesity, heart, lungs, liver or kidney disease, the company said.
Patients who had the highest viral levels, or produced the lowest levels of antibodies, were more likely to respond to treatment.
“We continue to see the strongest effects in patients at higher risk of poor outcomes due to high viral load.”said the company’s chief scientific officer, George Yancopoulos.
Regeneron treatment, called REGN-COV2, contains two monoclonal antibodies against the coronavirus spike protein.
It is considered one of the most promising potential coronavirus treatments being studied.
Preliminary results of a clinical trial that Regeneron announced in September showed that the drug can help treat coronary virus patients out of hospital by reducing virus levels and symptoms, the company said.
Experimental antibody therapies could become a powerful part of the arsenal that doctors use to treat patients who have acquired the coronavirus.
Anthony Fauci, America’s chief infectious disease officer, has referred to antibody-based drugs that could treat infected patients shortly after contracting the virus as a bridge to a vaccine.
Antibody therapies are also being studied in hospital to treat people with more serious cases, and as short-term treatments that could be given to people, such as nursing home residents or staff, who may have been exposed during a case. to prevent them becoming ill. Other companies testing antibody treatments include Eli Lilly & Co., AstraZeneca Plc and GlaxoSmithKline Plc along with their partner Vir Biotechnology Inc.